サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1475887

血管内皮増殖因子の世界市場：製品タイプ、エンドユーザー、地域別：産業分析、規模、シェア、成長、動向、予測（2024年～2031年）

Vascular Endothelial Growth Factor Market by Product Type, End-Users, and Geography : Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2031

出版日
ページ情報
英文 440 Pages
納期
2～5営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
血管内皮増殖因子の世界市場：製品タイプ、エンドユーザー、地域別：産業分析、規模、シェア、成長、動向、予測（2024年～2031年）
出版日: 2024年04月30日
発行: Persistence Market Research
ページ情報: 英文 440 Pages
納期: 2～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

血管内皮増殖因子（VEGF）市場は、医学研究の進歩と、血管に関連する様々な疾患や状態を治療するための効果的な治療法の必要性の高まりにより、近年大きな牽引力となっています。Persistence Market Researchのこの総合レポートは、VEGFの市場力学を詳細に調査し、市場規模、成長促進要因、課題、機会、競合情勢に関する主要な考察を掲載しています。分析対象期間は2024年～2031年で、利害関係者に戦略的意思決定と事業成長の指針となる貴重な情報を提供します。

世界のVEGF市場は、2024年～2031年にCAGR10.7%で拡大すると予測され、2024年の市場規模は2億6,170万米ドルと推定され、2031年には5億3,310万米ドルに達すると予測されます。

主な洞察

  • 市場価値推定（2024年）：2億6,170万米ドル
  • 予測市場価値（2031年）：5億3,311万米ドル
  • 世界市場成長率（CAGR 2024年～2031年）：10.7%

VEGF市場- レポート範囲：

この調査レポートは、VEGF市場の包括的な分析を提供し、成長を促進する主な要因をハイライトしています。VEGFは、新しい血管を形成するプロセスである血管新生におけるその役割により、抗がん治療の重要な標的です。抗VEGF療法は、様々な種類のがんや、加齢黄斑変性症（AMD）、糖尿病性網膜症、その他の網膜疾患などの治療に使用されています。がんと加齢関連疾患の発生率の増加は、医学研究と治療法の進歩と相まって、VEGF標的治療薬への需要を煽っています。

市場成長促進要因：

世界のがん罹患率の増加はVEGF市場の主要促進要因です。がん細胞の増殖と転移には新たな血管が必要であるため、抗VEGF療法は様々ながんの治療の要となっています。加えて、AMDのような加齢関連疾患の罹患率が上昇していることも、市場の成長にさらに寄与しています。ドラッグデリバリーシステムや個別化医療アプローチにおける技術の進歩は、より効果的で的を絞った治療法へとつながり、市場の拡大を促進しています。治療法の改善とVEGF阻害剤の新たな用途開拓に対する需要が、市場の成長を促す主な要因となっています。

市場抑制要因：

その可能性にもかかわらず、VEGF市場はある課題に直面しています。抗VEGF療法は高額であるため、特にヘルスケアシステムが発達していない地域では、一部の患者のアクセスが制限される可能性があります。さらに、高血圧や創傷治癒障害など、VEGF阻害剤に伴う副作用は患者にリスクをもたらす可能性があります。規制上のハードルや薬剤承認までの長いプロセスも市場の成長に影響を与えます。これらの要因が代替療法との競合と相まって、市場の拡大を抑制する可能性があります。

市場機会：

VEGF市場には、成長と技術革新の大きな機会があります。抗VEGF療法のバイオシミラーやジェネリック医薬品の開発は、より安価な治療法への道を提供し、より幅広い患者層へのアクセスを拡大します。VEGF阻害剤の新たな治療用途に関する継続的な研究は、市場の多様化の可能性を提供します。さらに、製薬会社と研究機関の共同研究は画期的な治療法を生み出し、VEGF市場の裾野を広げる可能性があります。先端治療への需要が高まっている新興市場への投資は、市場拡大のもう一つのチャンスです。

本レポートで扱う主な質問

  • 2024年～2031年のVEGF市場の予想CAGRは？
  • VEGF市場の成長を促進する主な要因は何か？
  • VEGF市場で最大のシェアを占める地域はどこか？
  • 世界のVEGF市場の主要企業は？
  • VEGF市場の主な成長機会は？

目次

第1章 エグゼクティブサマリー

第2章 市場概要

  • 市場範囲/ 分類
  • 市場の定義/ 範囲/ 制限
  • 包含と除外

第3章 主要な市場動向

  • 市場に影響を与える主な動向
  • 製品イノベーション/開発動向

第4章 主な内容

  • 粗利益分析
  • 規制シナリオ
  • バリューチェーン分析
  • VEGF市場金額比較（2019年と2023年）

第5章 市場背景

  • マクロ経済要因
  • 予測要因- 関連性と影響
  • 市場力学

第6章 COVID-19危機分析

  • COVID-19の現在の統計と今後の影響の可能性
  • 現在のGDP予測と予想される影響
  • 2008年と比較した現在の経済予測経済分析
  • COVID-19と影響分析
    • VEGFタイプ別
    • VGEF用途別
    • VEGF発現宿主別
    • エンドユーザー別
    • 地域別
  • 2023年の市場シナリオ

第7章 世界の血管内皮増殖因子（VEGF）市場の需要（金額または規模）分析

  • 過去の市場金額分析（2019年～2023年）
  • 現在・将来の市場金額予測（2024年～2031年）
    • 前年比成長動向分析
    • 絶対的利益の機会分析

第8章 世界の血管内皮増殖因子（VEGF）の市場分析：VEGFタイプ別

  • イントロダクション/主な調査結果
  • 過去の市場規模分析：VEGFタイプ別（2019年～2023年）
  • 現在・将来の市場規模分析・予測：VEGFタイプ別（2024年～2032年）
    • ヒトVEGF
    • マウスVEGF
    • ウサギVEGF
    • ラットVEGF
    • その他
  • VEGFタイプ別の市場魅力度分析

第9章 世界の血管内皮増殖因子（VEGF）市場分析：VGEF用途別

  • イントロダクション/主な調査結果
  • 過去の市場規模分析：VGEF用途別（2019年～2023年）
  • 現在・将来の市場規模分析・予測：VGEF用途別（2024年～2032年）
    • 細胞培養
    • 細胞ベースの治療
    • 医薬品開発
    • 遺伝子治療
    • 希少疾患の治療
    • 併用療法
    • 創傷治癒研究
    • 血液学研究
    • 骨形成
    • 抗血管新生療法
  • VGEF用途別の市場魅力度分析

第10章 世界の血管内皮増殖因子（VEGF）市場分析：発現宿主別

  • イントロダクション/主な調査結果
  • 過去の市場規模分析：発現宿主別（2019年～2023年）
  • 現在・将来の市場規模分析・予測：発現宿主別（2024年～2032年）
    • HEK293細胞
    • 大腸菌
    • 昆虫細胞
    • CHO
    • NS0
    • その他
  • 発現宿主別の市場魅力度分析

第11章 世界の血管内皮増殖因子（VEGF）市場分析：エンドユーザー別

  • イントロダクション/主な調査結果
  • 過去の市場規模分析：エンドユーザー別（2019年～2023年）
  • 現在・将来の市場規模分析・予測：エンドユーザー別（2024年～2032年）
    • 製薬・バイオテクノロジー企業
    • 研究センター・学術機関
    • CMOとCDMO
    • その他のエンドユーザー
  • エンドユーザー別の市場魅力度分析

第12章 世界の血管内皮増殖因子（VEGF）市場分析：地域別

  • イントロダクション
  • 過去の市場規模分析：地域別（2019年～2023年）
  • 現在・将来の市場規模分析・予測：地域別（2024年～2032年）
    • 北米
    • ラテンアメリカ
    • 欧州
    • 南アジア
    • 東アジア
    • オセアニア
    • 中東・アフリカ
  • 地域別の市場魅力度分析

第13章 北米の血管内皮増殖因子（VEGF）市場分析

第14章 ラテンアメリカの血管内皮増殖因子（VEGF）市場分析

第15章 欧州の血管内皮増殖因子（VEGF）市場分析

第16章 南アジアの血管内皮増殖因子（VEGF）市場分析

第17章 東アジアの血管内皮増殖因子（VEGF）市場分析

第18章 オセアニア血管内皮増殖因子（VEGF）市場分析

第19章 中東・アフリカ（MEA）の血管内皮増殖因子（VEGF）市場分析

第20章 市場構造分析

  • 企業階層別の市場分析
  • 主要企業の市場シェア分析
  • 市場プレゼンス分析

第21章 競合分析

  • 競合ダッシュボード
  • 競合ベンチマーク
  • 競合の深掘り
    • Thermo Fisher Scientific
    • Merck KGaA
    • Bio-Rad Laboratories, Inc.
    • Bio-Techne[R&D Systems, Inc.]
    • GenScript
    • Miltenyi Biotec.
    • Abcam PLC.
    • Sino Biological Inc.
    • Cell Signaling Technology, Inc.
    • ACROBiosystems
    • STEMCELL Technologies
    • Creative Bioarray
    • PeproTech
    • Applied Biological Materials（abm）Inc.
    • GenWay Biotech
    • Leadgene Biomedical, Inc.
    • Boster Bio
    • Prospec-Tany Technogene Ltd.
    • Proteintech Group, Inc

第22章 使用される前提条件と頭字語

第23章 調査手法

目次
Product Code: PMRREP33129

The Vascular Endothelial Growth Factor (VEGF) market has gained significant traction in recent years, driven by advances in medical research and the growing need for effective therapies to treat a range of vascular-related diseases and conditions. This comprehensive report from Persistence Market Research delves into the dynamics of the VEGF market, providing key insights into market size, growth drivers, challenges, opportunities, and competitive landscape. The analysis covers the period from 2024 to 2031, offering stakeholders valuable information to guide their strategic decisions and business growth.

The global VEGF market is projected to expand at a CAGR of 10.7% from 2024 to 2031, with a market value estimated at USD 261.7 million in 2024 and expected to reach USD 533.1 million by 2031.

Key Insights:

  • Market Value Estimate (2024): USD 261.7 Million
  • Projected Market Value (2031): USD 533.1 Billion
  • Global Market Growth Rate (CAGR 2024 to 2031): 10.7%

VEGF Market - Report Scope:

The report provides a comprehensive analysis of the VEGF market, highlighting key factors driving growth. VEGF is a significant target for anti-cancer therapies due to its role in angiogenesis, the process of forming new blood vessels. Anti-VEGF therapies are used to treat various types of cancers, as well as other conditions such as age-related macular degeneration (AMD), diabetic retinopathy, and other retinal diseases. The growing incidence of cancer and age-related diseases, coupled with advancements in medical research and treatment methods, has fueled demand for VEGF-targeting therapies.

Market Growth Drivers:

The increasing prevalence of cancer worldwide is a major driver for the VEGF market. As cancer cells require new blood vessels to grow and spread, anti-VEGF therapies have become a cornerstone in the treatment of various cancers. Additionally, the rising incidence of age-related diseases, such as AMD, has further contributed to market growth. Technological advancements in drug delivery systems and personalized medicine approaches have led to more effective and targeted therapies, fostering market expansion. The demand for improved treatments and the development of new applications for VEGF inhibitors are key factors driving the market's growth.

Market Restraints:

Despite its potential, the VEGF market faces certain challenges. The high cost of anti-VEGF therapies can limit access for some patients, especially in regions with less developed healthcare systems. Additionally, side effects associated with VEGF inhibitors, such as hypertension and impaired wound healing, can pose risks to patients. Regulatory hurdles and the lengthy process of drug approval also impact market growth. These factors, combined with competition from alternative therapies, can restrain the market's expansion.

Market Opportunities:

The VEGF market presents significant opportunities for growth and innovation. The development of biosimilars and generic versions of anti-VEGF therapies offers a pathway to more affordable treatments, expanding access to a broader patient base. Ongoing research into new therapeutic applications for VEGF inhibitors provides potential for market diversification. Furthermore, collaborations between pharmaceutical companies and research institutions can lead to groundbreaking treatments and expand the VEGF market's reach. Investment in emerging markets, where demand for advanced therapies is growing, represents another opportunity for market expansion.

Key Questions Addressed in the Report:

  • What is the expected CAGR for the VEGF market between 2024 and 2031?
  • What are the major factors driving growth in the VEGF market?
  • Which regions hold the largest share of the VEGF market?
  • Who are the key players in the global VEGF market?
  • What are the main opportunities for growth in the VEGF market?

Competitive Landscape and Business Strategies:

The VEGF market features a competitive landscape with leading players like Genentech, Regeneron Pharmaceuticals, and Amgen. These companies focus on innovation, research and development, and strategic collaborations to maintain their market position. Genentech's Avastin, a widely used anti-VEGF drug, is a prominent example of a successful product in this sector. Regeneron Pharmaceuticals has also gained a significant market share with its product Eylea, used in the treatment of AMD and other retinal diseases.

Key business strategies include the development of new drug formulations, expansion into new therapeutic areas, and partnerships with other pharmaceutical companies. Companies are also focusing on expanding their presence in emerging markets and exploring biosimilar opportunities to increase their market reach.

Key Companies Profiled:

  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne [R&D Systems, Inc.]
  • GenScript
  • Miltenyi Biotec.
  • Abcam PLC.
  • Sino Biological Inc.
  • Cell Signaling Technology, Inc.
  • ACROBiosystems
  • STEMCELL Technologies

VEGF Market Segmentation:

VEGF Market by VEGF Type:

  • Human VEGF
  • Mouse VEGF
  • Rat VEGF
  • Rabbit VEGF
  • Others VEGF

VEGF Market by Expression Host:

  • CHO
  • E. Coli
  • HEK
  • NSO
  • Insect Cells
  • Others

VEGF Market by Application:

  • Cell Culture
  • Cell-based Therapy
  • Drug Development
  • Gene Therapy
  • Rare Disease treatment
  • Wound Healing Research
  • Combination Therapies
  • Hematology Research
  • Osteogenesis
  • Anti-Angiogenic Therapy

VEGF Market by End User:

  • Pharmaceutical & Biotechnology Companies
  • Academic Institutes
  • CMOs & CDMOs
  • Other End Users

Research Centers & Laboratories

Hospital-attached Laboratories (HALs)

VEGF Market by Region:

  • North America VEGF Market
  • Latin America VEGF Market
  • Europe VEGF Market
  • South Asia VEGF Market
  • East Asia VEGF Market
  • Oceania VEGF Market
  • Middle East & Africa VEGF Market

Table of Contents

1. Executive Summary

  • 1.1. Global Market Outlook
  • 1.2. Demand Side Trends
  • 1.3. Supply Side Trends
  • 1.4. Analysis and Recommendations

2. Market Overview

  • 2.1. Market Coverage / Taxonomy
  • 2.2. Market Definition / Scope / Limitations
  • 2.3. Inclusion And Exclusions

3. Key Market Trends

  • 3.1. Key Trends Impacting the Market
  • 3.2. Product Innovation / Development Trends

4. Key Inclusions

  • 4.1. Gross Margin Analysis
  • 4.2. Regulatory Scenario
  • 4.3. Value Chain Analysis
  • 4.4. VEGF Market Value Comparison 2019 and 2023

5. Market Background

  • 5.1. Macro-Economic Factors
    • 5.1.1. Global GDP Growth Outlook
    • 5.1.2. Global Healthcare Spending Outlook
    • 5.1.3. Global Growth Factor Market Outlook
  • 5.2. Forecast Factors - Relevance & Impact
    • 5.2.1. Advancements in Protein Characterization Techniques
    • 5.2.2. Increase in R&D Funding and Grants
    • 5.2.3. High Prevalence of Chronic Diseases
    • 5.2.4. New Product Launch
    • 5.2.5. Rising Research Activities for Rare Disease Indications
    • 5.2.6. Emergence of Novel Patented Technologies
    • 5.2.7. Collaborations and Agreements between Manufacturers
    • 5.2.8. Regulatory Approvals
  • 5.3. Market Dynamics
    • 5.3.1. Drivers
    • 5.3.2. Restraints
    • 5.3.3. Opportunity Analysis

6. COVID-19 Crisis Analysis

  • 6.1. Current COVID-19 Statistics and Probable Future Impact
  • 6.2. Current GDP Projection and Probable Impact
  • 6.3. Current Economic Projection as compared to 2008 Economic analysis
  • 6.4. COVID-19 and Impact Analysis
    • 6.4.1. By VEGF Types
    • 6.4.2. By VGEF Application
    • 6.4.3. By VEGF Expression Hosts
    • 6.4.4. By End User
    • 6.4.5. By Region
  • 6.5. 2023 Market Scenario

7. Global Vascular Endothelial Growth Factor (VEGF) Market Demand (in Value or Size in US$ Mn) Analysis 2019-2023 and Forecast, 2024-2031

  • 7.1. Historical Market Value (US$ Mn) Analysis, 2019-2023
  • 7.2. Current and Future Market Value (US$ Mn) Projections, 2024-2031
    • 7.2.1. Y-o-Y Growth Trend Analysis
    • 7.2.2. Absolute $ Opportunity Analysis

8. Global Vascular Endothelial Growth Factor (VEGF) Market Analysis 2019-2023 and Forecast 2024-2031, By VEGF Types

  • 8.1. Introduction / Key Findings
  • 8.2. Historical Market Size (US$ Mn) Analysis By VEGF Types, 2019-2023
  • 8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By VEGF Types, 2024-2031
    • 8.3.1. Human VEGF
    • 8.3.2. Mouse VEGF
    • 8.3.3. Rabbit VEGF
    • 8.3.4. RAT VEGF
    • 8.3.5. Others
  • 8.4. Market Attractiveness Analysis By VEGF Types

9. Global Vascular Endothelial Growth Factor (VEGF) Market Analysis 2019-2023 and Forecast 2024-2031, By VGEF Application

  • 9.1. Introduction / Key Findings
  • 9.2. Historical Market Size (US$ Mn) Analysis By VGEF Application, 2019-2023
  • 9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By VGEF Application, 2024-2031
    • 9.3.1. Cell Culture
    • 9.3.2. Cell-Based Therapy
    • 9.3.3. Drug Development
    • 9.3.4. Gene Therapy
    • 9.3.5. Rare Disease Treatment
    • 9.3.6. Combination Therapies
    • 9.3.7. Wound Healing Research
    • 9.3.8. Hematology Research
    • 9.3.9. Osteogenesis
    • 9.3.10. Anti-Angiogenic Therapy
  • 9.4. Market Attractiveness Analysis By VGEF Application

10. Global Vascular Endothelial Growth Factor (VEGF) Market Analysis 2019-2023 and Forecast 2024-2031, By VEGF Expression Hosts

  • 10.1. Introduction / Key Findings
  • 10.2. Historical Market Size (US$ Mn) Analysis By VGEF Expression Hosts, 2019-2023
  • 10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By VGEF Expression Hosts, 2024-2031
    • 10.3.1. HEK293 cells
    • 10.3.2. E. coli
    • 10.3.3. Insect Cells
    • 10.3.4. CHO
    • 10.3.5. NS0
    • 10.3.6. Others
  • 10.4. Market Attractiveness Analysis By VGEF Expression Hosts

11. Global Vascular Endothelial Growth Factor (VEGF) Market Analysis 2019-2023 and Forecast 2024-2031, by End User

  • 11.1. Introduction / Key Findings
  • 11.2. Historical Market Size (US$ Mn) Analysis By End User, 2019-2023
  • 11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By End User, 2024-2031
    • 11.3.1. Pharmaceutical and Biotechnology Companies
    • 11.3.2. Research Centers & Academic Institutes
    • 11.3.3. CMO and CDMO
    • 11.3.4. Other End Users
      • 11.3.4.1. Research laboratories
      • 11.3.4.2. Hospital-Attached laboratories (HALs)
  • 11.4. Market Attractiveness Analysis By End User

12. Global Vascular Endothelial Growth Factor (VEGF) Market Analysis 2019-2023 and Forecast 2024-2031, by Region

  • 12.1. Introduction
  • 12.2. Historical Market Size (US$ Mn) Analysis By Region, 2019-2023
  • 12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Region, 2024-2031
    • 12.3.1. North America
    • 12.3.2. Latin America
    • 12.3.3. Europe
    • 12.3.4. South Asia
    • 12.3.5. East Asia
    • 12.3.6. Oceania
    • 12.3.7. Middle East and Africa
  • 12.4. Market Attractiveness Analysis By Region

13. North America Vascular Endothelial Growth Factor (VEGF) Market Analysis 2019-2023 and Forecast 2024-2031

  • 13.1. Introduction
  • 13.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
  • 13.3. Current and Future Market Size (US$ Mn) Analysis Forecast By Market Taxonomy, 2024-2031
    • 13.3.1. By Country
      • 13.3.1.1. U.S.
      • 13.3.1.2. Canada
    • 13.3.2. By VEGF Types
    • 13.3.3. By VGEF Application
    • 13.3.4. By VGEF Expression Hosts
    • 13.3.5. By End User
  • 13.4. Market Attractiveness Analysis
    • 13.4.1. By Country
    • 13.4.2. By VEGF Types
    • 13.4.3. By VGEF Application
    • 13.4.4. By VGEF Expression Hosts
    • 13.4.5. By End User
  • 13.5. Key Market Participants - Intensity Mapping
  • 13.6. Drivers and Restraints - Impact Analysis
  • 13.7. Country Level Analysis & Forecast
    • 13.7.1. U.S. Vascular Endothelial Growth Factor (VEGF) Market
      • 13.7.1.1. Introduction
      • 13.7.1.2. Market Analysis and Forecast by Market Taxonomy
        • 13.7.1.2.1. By VEGF Types
        • 13.7.1.2.2. By VGEF Application
        • 13.7.1.2.3. By VGEF Expression Hosts
        • 13.7.1.2.4. By End User
    • 13.7.2. Canada Vascular Endothelial Growth Factor (VEGF) Market
      • 13.7.2.1. Introduction
      • 13.7.2.2. Market Analysis and Forecast by Market Taxonomy
        • 13.7.2.2.1. By VEGF Types
        • 13.7.2.2.2. By VGEF Application
        • 13.7.2.2.3. By VGEF Expression Hosts
        • 13.7.2.2.4. By End User

14. Latin America Vascular Endothelial Growth Factor (VEGF) Market Analysis 2019-2023 and Forecast 2024-2031

  • 14.1. Introduction
  • 14.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
  • 14.3. Current and Future Market Size (US$ Mn) Analysis Forecast By Market Taxonomy, 2024-2031
    • 14.3.1. By Country
      • 14.3.1.1. Brazil
      • 14.3.1.2. Mexico
      • 14.3.1.3. Argentina
      • 14.3.1.4. Rest of Latin America
    • 14.3.2. By VEGF Types
    • 14.3.3. By VGEF Application
    • 14.3.4. By VGEF Expression Hosts
    • 14.3.5. By End User
  • 14.4. Market Attractiveness Analysis
    • 14.4.1. By Country
    • 14.4.2. By VEGF Types
    • 14.4.3. By VGEF Application
    • 14.4.4. By VGEF Expression Hosts
    • 14.4.5. By End User
  • 14.5. Key Market Participants - Intensity Mapping
  • 14.6. Drivers and Restraints - Impact Analysis
  • 14.7. Country Level Analysis & Forecast
    • 14.7.1. Brazil Vascular Endothelial Growth Factor (VEGF) Market
      • 14.7.1.1. Introduction
      • 14.7.1.2. Market Analysis and Forecast by Market Taxonomy
        • 14.7.1.2.1. By VEGF Types
        • 14.7.1.2.2. By VGEF Application
        • 14.7.1.2.3. By VGEF Expression Hosts
        • 14.7.1.2.4. By End User
    • 14.7.2. Argentina Vascular Endothelial Growth Factor (VEGF) Market
      • 14.7.2.1. Introduction
      • 14.7.2.2. Market Analysis and Forecast by Market Taxonomy
        • 14.7.2.2.1. By VEGF Types
        • 14.7.2.2.2. By VGEF Application
        • 14.7.2.2.3. By VGEF Expression Hosts
        • 14.7.2.2.4. By End User
    • 14.7.3. Mexico Vascular Endothelial Growth Factor (VEGF) Market
      • 14.7.3.1. Introduction
      • 14.7.3.2. Market Analysis and Forecast by Market Taxonomy
        • 14.7.3.2.1. By VEGF Types
        • 14.7.3.2.2. By VGEF Application
        • 14.7.3.2.3. By VGEF Expression Hosts
        • 14.7.3.2.4. By End User

15. Europe Vascular Endothelial Growth Factor (VEGF) Market Analysis 2019-2023 and Forecast 2024-2031

  • 15.1. Introduction
  • 15.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
  • 15.3. Current and Future Market Size (US$ Mn) Analysis Forecast By Market Taxonomy, 2024-2031
    • 15.3.1. By Country
      • 15.3.1.1. Germany
      • 15.3.1.2. Italy
      • 15.3.1.3. France
      • 15.3.1.4. U.K.
      • 15.3.1.5. Spain
      • 15.3.1.6. BENELUX
      • 15.3.1.7. Russia
      • 15.3.1.8. Nordic Countries
      • 15.3.1.9. Rest of Europe
    • 15.3.2. By VEGF Types
    • 15.3.3. By VGEF Application
    • 15.3.4. By VGEF Expression Hosts
    • 15.3.5. By End User
  • 15.4. Market Attractiveness Analysis
    • 15.4.1. By Country
    • 15.4.2. By VEGF Types
    • 15.4.3. By VGEF Application
    • 15.4.4. By VGEF Expression Hosts
    • 15.4.5. By End User
  • 15.5. Key Market Participants - Intensity Mapping
  • 15.6. Drivers and Restraints - Impact Analysis
  • 15.7. Country Level Analysis & Forecast
    • 15.7.1. Germany Vascular Endothelial Growth Factor (VEGF) Market
      • 15.7.1.1. Introduction
      • 15.7.1.2. Market Analysis and Forecast by Market Taxonomy
        • 15.7.1.2.1. By VEGF Types
        • 15.7.1.2.2. By VGEF Application
        • 15.7.1.2.3. By VGEF Expression Hosts
        • 15.7.1.2.4. By End User
    • 15.7.2. France Vascular Endothelial Growth Factor (VEGF) Market
      • 15.7.2.1. Introduction
      • 15.7.2.2. Market Analysis and Forecast by Market Taxonomy
        • 15.7.2.2.1. By VEGF Types
        • 15.7.2.2.2. By VGEF Application
        • 15.7.2.2.3. By VGEF Expression Hosts
        • 15.7.2.2.4. By End User
    • 15.7.3. Italy Vascular Endothelial Growth Factor (VEGF) Market
      • 15.7.3.1. Introduction
      • 15.7.3.2. Market Analysis and Forecast by Market Taxonomy
        • 15.7.3.2.1. By VEGF Types
        • 15.7.3.2.2. By VGEF Application
        • 15.7.3.2.3. By VGEF Expression Hosts
        • 15.7.3.2.4. By End User
    • 15.7.4. Spain Vascular Endothelial Growth Factor (VEGF) Market
      • 15.7.4.1. Introduction
      • 15.7.4.2. Market Analysis and Forecast by Market Taxonomy
        • 15.7.4.2.1. By VEGF Types
        • 15.7.4.2.2. By VGEF Application
        • 15.7.4.2.3. By VGEF Expression Hosts
        • 15.7.4.2.4. By End User
    • 15.7.5. U.K. Vascular Endothelial Growth Factor (VEGF) Market
      • 15.7.5.1. Introduction
      • 15.7.5.2. Market Analysis and Forecast by Market Taxonomy
        • 15.7.5.2.1. By VEGF Types
        • 15.7.5.2.2. By VGEF Application
        • 15.7.5.2.3. By VGEF Expression Hosts
        • 15.7.5.2.4. By End User
    • 15.7.6. Benelux Vascular Endothelial Growth Factor (VEGF) Market
      • 15.7.6.1. Introduction
      • 15.7.6.2. Market Analysis and Forecast by Market Taxonomy
        • 15.7.6.2.1. By VEGF Types
        • 15.7.6.2.2. By VGEF Application
        • 15.7.6.2.3. By VGEF Expression Hosts
        • 15.7.6.2.4. By End User
    • 15.7.7. Nordic Countries Vascular Endothelial Growth Factor (VEGF) Market
      • 15.7.7.1. Introduction
      • 15.7.7.2. Market Analysis and Forecast by Market Taxonomy
        • 15.7.7.2.1. By VEGF Types
        • 15.7.7.2.2. By VGEF Application
        • 15.7.7.2.3. By VGEF Expression Hosts
        • 15.7.7.2.4. By End User
    • 15.7.8. Russia Vascular Endothelial Growth Factor (VEGF) Market
      • 15.7.8.1. Introduction
      • 15.7.8.2. Market Analysis and Forecast by Market Taxonomy
        • 15.7.8.2.1. By VEGF Types
        • 15.7.8.2.2. By VGEF Application
        • 15.7.8.2.3. By VGEF Expression Hosts
        • 15.7.8.2.4. By End User

16. South Asia Vascular Endothelial Growth Factor (VEGF) Market Analysis 2019-2023 and Forecast 2024-2031

  • 16.1. Introduction
  • 16.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
  • 16.3. Current and Future Market Size (US$ Mn) Analysis Forecast By Market Taxonomy, 2024-2031
    • 16.3.1. By Country
      • 16.3.1.1. India
      • 16.3.1.2. Thailand
      • 16.3.1.3. Indonesia
      • 16.3.1.4. Malaysia
      • 16.3.1.5. Rest of South Asia
    • 16.3.2. By VEGF Types
    • 16.3.3. By VGEF Application
    • 16.3.4. By VGEF Expression Hosts
    • 16.3.5. By End User
  • 16.4. Market Attractiveness Analysis
    • 16.4.1. By Country
    • 16.4.2. By VEGF Types
    • 16.4.3. By VGEF Application
    • 16.4.4. By VGEF Expression Hosts
    • 16.4.5. By End User
  • 16.5. Key Market Participants - Intensity Mapping
  • 16.6. Drivers and Restraints - Impact Analysis
  • 16.7. Country Level Analysis & Forecast
    • 16.7.1. India Vascular Endothelial Growth Factor (VEGF) Market
      • 16.7.1.1. Introduction
      • 16.7.1.2. Market Analysis and Forecast by Market Taxonomy
        • 16.7.1.2.1. By VEGF Types
        • 16.7.1.2.2. By VGEF Application
        • 16.7.1.2.3. By VGEF Expression Hosts
        • 16.7.1.2.4. By End User
    • 16.7.2. Indonesia Vascular Endothelial Growth Factor (VEGF) Market
      • 16.7.2.1. Introduction
      • 16.7.2.2. Market Analysis and Forecast by Market Taxonomy
        • 16.7.2.2.1. By VEGF Types
        • 16.7.2.2.2. By VGEF Application
        • 16.7.2.2.3. By VGEF Expression Hosts
        • 16.7.2.2.4. By End User
    • 16.7.3. Malaysia Vascular Endothelial Growth Factor (VEGF) Market
      • 16.7.3.1. Introduction
      • 16.7.3.2. Market Analysis and Forecast by Market Taxonomy
        • 16.7.3.2.1. By VEGF Types
        • 16.7.3.2.2. By VGEF Application
        • 16.7.3.2.3. By VGEF Expression Hosts
        • 16.7.3.2.4. By End User
    • 16.7.4. Thailand Vascular Endothelial Growth Factor (VEGF) Market
      • 16.7.4.1. Introduction
      • 16.7.4.2. Market Analysis and Forecast by Market Taxonomy
        • 16.7.4.2.1. By VEGF Types
        • 16.7.4.2.2. By VGEF Application
        • 16.7.4.2.3. By VGEF Expression Hosts
        • 16.7.4.2.4. By End User

17. East Asia Vascular Endothelial Growth Factor (VEGF) Market Analysis 2019-2023 and Forecast 2024-2031

  • 17.1. Introduction
  • 17.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
  • 17.3. Current and Future Market Size (US$ Mn) Analysis Forecast By Market Taxonomy, 2024-2031
    • 17.3.1. By Country
      • 17.3.1.1. China
      • 17.3.1.2. Japan
      • 17.3.1.3. South Korea
    • 17.3.2. By VEGF Types
    • 17.3.3. By VGEF Application
    • 17.3.4. By VGEF Expression Hosts
    • 17.3.5. By End User
  • 17.4. Market Attractiveness Analysis
    • 17.4.1. By Country
    • 17.4.2. By VEGF Types
    • 17.4.3. By VGEF Application
    • 17.4.4. By VGEF Expression Hosts
    • 17.4.5. By End User
  • 17.5. Key Market Participants - Intensity Mapping
  • 17.6. Drivers and Restraints - Impact Analysis
  • 17.7. Country Level Analysis & Forecast
    • 17.7.1. China Vascular Endothelial Growth Factor (VEGF) Market
      • 17.7.1.1. Introduction
      • 17.7.1.2. Market Analysis and Forecast by Market Taxonomy
        • 17.7.1.2.1. By VEGF Types
        • 17.7.1.2.2. By VGEF Application
        • 17.7.1.2.3. By VGEF Expression Hosts
        • 17.7.1.2.4. By End User
    • 17.7.2. Japan Vascular Endothelial Growth Factor (VEGF) Market
      • 17.7.2.1. Introduction
      • 17.7.2.2. Market Analysis and Forecast by Market Taxonomy
        • 17.7.2.2.1. By VEGF Types
        • 17.7.2.2.2. By VGEF Application
        • 17.7.2.2.3. By VGEF Expression Hosts
        • 17.7.2.2.4. By End User
    • 17.7.3. South Korea Vascular Endothelial Growth Factor (VEGF) Market
      • 17.7.3.1. Introduction
      • 17.7.3.2. Market Analysis and Forecast by Market Taxonomy
        • 17.7.3.2.1. By VEGF Types
        • 17.7.3.2.2. By VGEF Application
        • 17.7.3.2.3. By VGEF Expression Hosts
        • 17.7.3.2.4. By End User

18. Oceania Vascular Endothelial Growth Factor (VEGF) Market Analysis 2019-2023 and Forecast 2024-2031

  • 18.1. Introduction
  • 18.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
  • 18.3. Current and Future Market Size (US$ Mn) Analysis Forecast By Market Taxonomy, 2024-2031
    • 18.3.1. By Country
      • 18.3.1.1. Australia
      • 18.3.1.2. New Zealand
    • 18.3.2. By VEGF Types
    • 18.3.3. By VGEF Application
    • 18.3.4. By VGEF Expression Hosts
    • 18.3.5. By End User
  • 18.4. Market Attractiveness Analysis
    • 18.4.1. By Country
    • 18.4.2. By VEGF Types
    • 18.4.3. By VGEF Application
    • 18.4.4. By VGEF Expression Hosts
    • 18.4.5. By End User
  • 18.5. Key Market Participants - Intensity Mapping
  • 18.6. Drivers and Restraints - Impact Analysis
  • 18.7. Country Level Analysis & Forecast
    • 18.7.1. Australia Vascular Endothelial Growth Factor (VEGF) Market
      • 18.7.1.1. Introduction
      • 18.7.1.2. Market Analysis and Forecast by Market Taxonomy
        • 18.7.1.2.1. By VEGF Types
        • 18.7.1.2.2. By VGEF Application
        • 18.7.1.2.3. By VGEF Expression Hosts
        • 18.7.1.2.4. By End User
    • 18.7.2. New Zealand Vascular Endothelial Growth Factor (VEGF) Market
      • 18.7.2.1. Introduction
      • 18.7.2.2. Market Analysis and Forecast by Market Taxonomy
        • 18.7.2.2.1. By VEGF Types
        • 18.7.2.2.2. By VGEF Application
        • 18.7.2.2.3. By VGEF Expression Hosts
        • 18.7.2.2.4. By End User

19. Middle East and Africa (MEA) Vascular Endothelial Growth Factor (VEGF) Market Analysis 2019-2023 and Forecast 2024-2031

  • 19.1. Introduction
  • 19.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
  • 19.3. Current and Future Market Size (US$ Mn) Analysis Forecast By Market Taxonomy, 2024-2031
    • 19.3.1. By Country
      • 19.3.1.1. GCC Countries
      • 19.3.1.2. Turkey
      • 19.3.1.3. North Africa
      • 19.3.1.4. South Africa
      • 19.3.1.5. Rest of Middle East and Africa
    • 19.3.2. By VEGF Types
    • 19.3.3. By VGEF Application
    • 19.3.4. By VGEF Expression Hosts
    • 19.3.5. By End User
  • 19.4. Market Attractiveness Analysis
    • 19.4.1. By Country
    • 19.4.2. By VEGF Types
    • 19.4.3. By VGEF Application
    • 19.4.4. By VGEF Expression Hosts
    • 19.4.5. By End User
  • 19.5. Key Market Participants - Intensity Mapping
  • 19.6. Drivers and Restraints - Impact Analysis
  • 19.7. Country Level Analysis & Forecast
    • 19.7.1. GCC Countries Vascular Endothelial Growth Factor (VEGF) Market
      • 19.7.1.1. Introduction
      • 19.7.1.2. Market Analysis and Forecast by Market Taxonomy
        • 19.7.1.2.1. By VEGF Types
        • 19.7.1.2.2. By VGEF Application
        • 19.7.1.2.3. By VGEF Expression Hosts
        • 19.7.1.2.4. By End User
    • 19.7.2. Turkey Vascular Endothelial Growth Factor (VEGF) Market
      • 19.7.2.1. Introduction
      • 19.7.2.2. Market Analysis and Forecast by Market Taxonomy
        • 19.7.2.2.1. By VEGF Types
        • 19.7.2.2.2. By VGEF Application
        • 19.7.2.2.3. By VGEF Expression Hosts
        • 19.7.2.2.4. By End User
    • 19.7.3. South Africa Vascular Endothelial Growth Factor (VEGF) Market
      • 19.7.3.1. Introduction
      • 19.7.3.2. Market Analysis and Forecast by Market Taxonomy
        • 19.7.3.2.1. By VEGF Types
        • 19.7.3.2.2. By VGEF Application
        • 19.7.3.2.3. By VGEF Expression Hosts
        • 19.7.3.2.4. By End User
    • 19.7.4. North Africa Vascular Endothelial Growth Factor (VEGF) Market
      • 19.7.4.1. Introduction
      • 19.7.4.2. Market Analysis and Forecast by Market Taxonomy
        • 19.7.4.2.1. By VEGF Types
        • 19.7.4.2.2. By VGEF Application
        • 19.7.4.2.3. By VGEF Expression Hosts
        • 19.7.4.2.4. By End User

20. Market Structure Analysis

  • 20.1. Market Analysis by Tier of Companies
  • 20.2. Market Share Analysis of Top Players
  • 20.3. Market Presence Analysis
    • 20.3.1. By Regional footprint of Players
    • 20.3.2. Device foot print by Players
    • 20.3.3. Channel Foot Print by Players

21. Competition Analysis

  • 21.1. Competition Dashboard
  • 21.2. Competition Benchmarking
  • 21.3. Competition Deep Dive
    • 21.3.1. Thermo Fisher Scientific
      • 21.3.1.1. Overview & Key financials
      • 21.3.1.2. Product Portfolio
      • 21.3.1.3. Key Financials
      • 21.3.1.4. Sales Footprint
      • 21.3.1.5. SWOT Analysis
      • 21.3.1.6. Analysis Commentary
      • 21.3.1.7. Strategy Overview
    • 21.3.2. Merck KGaA
      • 21.3.2.1. Overview & Key financials
      • 21.3.2.2. Product Portfolio
      • 21.3.2.3. Key Financials
      • 21.3.2.4. Sales Footprint
      • 21.3.2.5. SWOT Analysis
      • 21.3.2.6. Analysis Commentary
      • 21.3.2.7. Strategy Overview
    • 21.3.3. Bio-Rad Laboratories, Inc.
      • 21.3.3.1. Overview & Key financials
      • 21.3.3.2. Product Portfolio
      • 21.3.3.3. Key Financials
      • 21.3.3.4. Sales Footprint
      • 21.3.3.5. SWOT Analysis
      • 21.3.3.6. Analysis Commentary
      • 21.3.3.7. Strategy Overview
    • 21.3.4. Bio-Techne [R&D Systems, Inc.]
      • 21.3.4.1. Overview & Key financials
      • 21.3.4.2. Product Portfolio
      • 21.3.4.3. Key Financials
      • 21.3.4.4. Sales Footprint
      • 21.3.4.5. SWOT Analysis
      • 21.3.4.6. Analysis Commentary
      • 21.3.4.7. Strategy Overview
    • 21.3.5. GenScript
      • 21.3.5.1. Overview & Key financials
      • 21.3.5.2. Product Portfolio
      • 21.3.5.3. Key Financials
      • 21.3.5.4. Sales Footprint
      • 21.3.5.5. SWOT Analysis
      • 21.3.5.6. Analysis Commentary
      • 21.3.5.7. Strategy Overview
    • 21.3.6. Miltenyi Biotec.
      • 21.3.6.1. Overview & Key financials
      • 21.3.6.2. Product Portfolio
      • 21.3.6.3. Key Financials
      • 21.3.6.4. Sales Footprint
      • 21.3.6.5. SWOT Analysis
      • 21.3.6.6. Analysis Commentary
      • 21.3.6.7. Strategy Overview
    • 21.3.7. Abcam PLC.
      • 21.3.7.1. Overview & Key financials
      • 21.3.7.2. Product Portfolio
      • 21.3.7.3. Key Financials
      • 21.3.7.4. Sales Footprint
      • 21.3.7.5. SWOT Analysis
      • 21.3.7.6. Analysis Commentary
      • 21.3.7.7. Strategy Overview
    • 21.3.8. Sino Biological Inc.
      • 21.3.8.1. Overview & Key financials
      • 21.3.8.2. Product Portfolio
      • 21.3.8.3. Key Financials
      • 21.3.8.4. Sales Footprint
      • 21.3.8.5. SWOT Analysis
      • 21.3.8.6. Analysis Commentary
      • 21.3.8.7. Strategy Overview
    • 21.3.9. Cell Signaling Technology, Inc.
      • 21.3.9.1. Overview & Key financials
      • 21.3.9.2. Product Portfolio
      • 21.3.9.3. Key Financials
      • 21.3.9.4. Sales Footprint
      • 21.3.9.5. SWOT Analysis
      • 21.3.9.6. Analysis Commentary
      • 21.3.9.7. Strategy Overview
    • 21.3.10. ACROBiosystems
      • 21.3.10.1. Overview & Key financials
      • 21.3.10.2. Product Portfolio
      • 21.3.10.3. Key Financials
      • 21.3.10.4. Sales Footprint
      • 21.3.10.5. SWOT Analysis
      • 21.3.10.6. Analysis Commentary
      • 21.3.10.7. Strategy Overview
    • 21.3.11. STEMCELL Technologies
      • 21.3.11.1. Overview & Key financials
      • 21.3.11.2. Product Portfolio
      • 21.3.11.3. Key Financials
      • 21.3.11.4. Sales Footprint
      • 21.3.11.5. SWOT Analysis
      • 21.3.11.6. Analysis Commentary
      • 21.3.11.7. Strategy Overview
    • 21.3.12. Creative Bioarray
      • 21.3.12.1. Overview & Key financials
      • 21.3.12.2. Product Portfolio
      • 21.3.12.3. Key Financials
      • 21.3.12.4. Sales Footprint
      • 21.3.12.5. SWOT Analysis
      • 21.3.12.6. Analysis Commentary
      • 21.3.12.7. Strategy Overview
    • 21.3.13. PeproTech
      • 21.3.13.1. Overview & Key financials
      • 21.3.13.2. Product Portfolio
      • 21.3.13.3. Key Financials
      • 21.3.13.4. Sales Footprint
      • 21.3.13.5. SWOT Analysis
      • 21.3.13.6. Analysis Commentary
      • 21.3.13.7. Strategy Overview
    • 21.3.14. Applied Biological Materials (abm) Inc.
      • 21.3.14.1. Overview & Key financials
      • 21.3.14.2. Product Portfolio
      • 21.3.14.3. Key Financials
      • 21.3.14.4. Sales Footprint
      • 21.3.14.5. SWOT Analysis
      • 21.3.14.6. Analysis Commentary
      • 21.3.14.7. Strategy Overview
    • 21.3.15. GenWay Biotech
      • 21.3.15.1. Overview & Key financials
      • 21.3.15.2. Product Portfolio
      • 21.3.15.3. Key Financials
      • 21.3.15.4. Sales Footprint
      • 21.3.15.5. SWOT Analysis
      • 21.3.15.6. Analysis Commentary
      • 21.3.15.7. Strategy Overview
    • 21.3.16. Leadgene Biomedical, Inc.
      • 21.3.16.1. Overview & Key financials
      • 21.3.16.2. Product Portfolio
      • 21.3.16.3. Key Financials
      • 21.3.16.4. Sales Footprint
      • 21.3.16.5. SWOT Analysis
      • 21.3.16.6. Analysis Commentary
      • 21.3.16.7. Strategy Overview
    • 21.3.17. Boster Bio
      • 21.3.17.1. Overview & Key financials
      • 21.3.17.2. Product Portfolio
      • 21.3.17.3. Key Financials
      • 21.3.17.4. Sales Footprint
      • 21.3.17.5. SWOT Analysis
      • 21.3.17.6. Analysis Commentary
      • 21.3.17.7. Strategy Overview
    • 21.3.18. Prospec-Tany Technogene Ltd.
      • 21.3.18.1. Overview & Key financials
      • 21.3.18.2. Product Portfolio
      • 21.3.18.3. Key Financials
      • 21.3.18.4. Sales Footprint
      • 21.3.18.5. SWOT Analysis
      • 21.3.18.6. Analysis Commentary
      • 21.3.18.7. Strategy Overview
    • 21.3.19. Proteintech Group, Inc
      • 21.3.19.1. Overview & Key financials
      • 21.3.19.2. Product Portfolio
      • 21.3.19.3. Key Financials
      • 21.3.19.4. Sales Footprint
      • 21.3.19.5. SWOT Analysis
      • 21.3.19.6. Analysis Commentary
      • 21.3.19.7. Strategy Overview

22. Assumptions and Acronyms Used

23. Research Methodology